Patents by Inventor Alexandre Lebedev
Alexandre Lebedev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240140982Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: September 14, 2023Publication date: May 2, 2024Applicant: TriLink Biotechnologies, LLCInventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Patent number: 11878991Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7 Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: November 6, 2020Date of Patent: January 23, 2024Assignee: TriLink BioTechnologies, LLCInventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Patent number: 11578095Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: May 26, 2022Date of Patent: February 14, 2023Assignee: TriLink Biotechnologies, LLCInventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Publication number: 20220289786Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: May 26, 2022Publication date: September 15, 2022Applicant: TriLink Biotechnologies, LLCInventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Patent number: 11414453Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: August 2, 2021Date of Patent: August 16, 2022Assignee: TriLink Biotechnologies, LLCInventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Publication number: 20210395729Abstract: The present invention includes compositions and methods for the treatment of a medical condition or disease utilizing editing oligonucleotides. The editing oligonucleotides contain a an oligonucleotide strand of about 10 to about 50 nucleotides on each side of the editing moiety which may contain a sugar or linker that positions the active editing moiety in the proper location for hybridization to the target nucleic acid. The editing oligonucleotides may also contain at least one nucleotide sequence change from the targeted sequence in the genome. The method includes modifying a genomic sequence within a cell utilizing an editing oligonucleotide without additional proteins or nucleic acids to assist in the editing process. The editing oligonucleotide may comprise backbone modifications that increase the nuclease stability of the oligonucleotide as compared to unmodified oligonucleotides or oligonucleotides having three phosphorothioates on each terminus.Type: ApplicationFiled: December 11, 2015Publication date: December 23, 2021Inventors: Tod M. WOOLF, Alexandre LEBEDEV, Richard I. HOGREFE
-
Publication number: 20210371452Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: August 2, 2021Publication date: December 2, 2021Applicant: TriLink Biotechnologies, LLCInventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Publication number: 20210261597Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7 Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: November 6, 2020Publication date: August 26, 2021Applicant: TriLink Biotechnologies, LLCInventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Patent number: 10913768Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: September 20, 2016Date of Patent: February 9, 2021Assignee: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Patent number: 10519189Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: December 26, 2018Date of Patent: December 31, 2019Assignee: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Patent number: 10494399Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: GrantFiled: April 1, 2019Date of Patent: December 3, 2019Assignee: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Publication number: 20190270766Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: April 1, 2019Publication date: September 5, 2019Applicant: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Publication number: 20190144490Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: December 26, 2018Publication date: May 16, 2019Applicant: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
-
Publication number: 20180273576Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.Type: ApplicationFiled: September 20, 2016Publication date: September 27, 2018Applicant: TRILINK BIOTECHNOLOGIES, INC.Inventors: Richard I. HOGREFE, Alexandre LEBEDEV, Anton P. MCCAFFREY, Dongwon SHIN
-
Publication number: 20170275672Abstract: Provided herein are methods for ligation of polynucleotides containing modified ligation components, particularly modified ligase cofactors, modified acceptors and modified donors. The methods readily applied to ligation-based assays for detection of a nucleic acid sequence where the use of the modified cofactor improves discrimination between matched and mismatched templates. Furthermore, the use of the modified ligation components reduces or eliminates the ligation in the absence of nucleic acid template. In addition, methods are applied to the preparation of nucleic acid libraries using modified acceptor probes and modified donor probes that reduce or eliminate probe dimerization during the ligation process.Type: ApplicationFiled: April 24, 2017Publication date: September 28, 2017Applicant: TriLink BioTechnologies, Inc.Inventors: Natasha Paul, Sabrina Shore, Jonathan Shum, Alexandre Lebedev, Gerald Zon
-
Patent number: 9631227Abstract: Provided herein are methods for ligation of polynucleotides containing modified ligation components, particularly modified ligase cofactors, modified acceptors and modified donors. The methods readily applied to ligation-based assays for detection of a nucleic acid sequence where the use of the modified cofactor improves discrimination between matched and mismatched templates. Furthermore, the use of the modified ligation components reduces or eliminates the ligation in the absence of nucleic acid template. In addition, methods are applied to the preparation of nucleic acid libraries using modified acceptor probes and modified donor probes that reduce or eliminate probe dimerization during the ligation process.Type: GrantFiled: March 15, 2013Date of Patent: April 25, 2017Assignee: TRILINK BIOTECHNOLOGIES, INC.Inventors: Natasha Paul, Sabrina Shore, Jonathan Shum, Alexandre Lebedev, Gerald Zon
-
Publication number: 20140323354Abstract: Provided herein are methods for ligation of polynucleotides containing modified ligation components, particularly modified ligase cofactors, modified acceptors and modified donors. The methods readily applied to ligation-based assays for detection of a nucleic acid sequence where the use of the modified cofactor improves discrimination between matched and mismatched templates. Furthermore, the use of the modified ligation components reduces or eliminates the ligation in the absence of nucleic acid template. In addition, methods are applied to the preparation of nucleic acid libraries using modified acceptor probes and modified donor probes that reduce or eliminate probe dimerization during the ligation process.Type: ApplicationFiled: March 15, 2013Publication date: October 30, 2014Applicant: Trilink BioTechnologies, Inc.Inventors: Natasha Paul, Sabrina Shore, Jonathan Shum, Alexandre Lebedev, Gerald Zon
-
Patent number: 8728725Abstract: Provided herein are methods for ligation of polynucleotides containing modified ligation components, particularly modified ligase cofactors, modified acceptors and modified donors. The methods readily applied to ligation-based assays for detection of a nucleic acid sequence where the use of the modified cofactor improves discrimination between matched and mismatched templates. Furthermore, the use of the modified ligation components reduces or eliminates the ligation in the absence of nucleic acid template.Type: GrantFiled: July 6, 2010Date of Patent: May 20, 2014Assignee: Trilink BiotechnologiesInventors: Natasha Paul, Jonathan Shum, Alexandre Lebedev, Gerald Zon
-
Publication number: 20140038181Abstract: Provided herein are methods for ligase mediated nucleic acid replication and amplification of oligo- and probes containing substituted ligase components, particularly substituted ligase cofactors, substituted oligo- and probe acceptors, substituted oligo- and probe donors, substituted adenylated oligo- and polynucleotide donor intermediates carrying thermolabile group or groups. The substituted ligase components are not active until Hot Start activation step converts them into unsubstituted or natural ligase components, which fully support ligase reaction. The described methods are readily applied to ligation-based assays, especially utilizing Ligase Chain Reaction (LCR), for detection of a nucleic acid sequence where the use of the substituted ligase components improves an overall efficiency of LCR, increase discrimination between matched and mismatched templates and reduces or eliminates appearance of false positive signal.Type: ApplicationFiled: July 3, 2013Publication date: February 6, 2014Inventors: Alexandre LEBEDEV, Inna KOUKHAREVA
-
Patent number: 8361753Abstract: The present invention provides methods and compositions for nucleic acid amplification. These methods involve the use of oligonucleotide primers in temperature dependent nucleic acid amplification reactions. In certain aspects, the methods are accomplished by use of certain modified oligonucleotide primers which provide utility in nucleic acid amplification. In preferred embodiments, the oligonucleotide primers are modified with particular chemical groups such as esters.Type: GrantFiled: May 17, 2007Date of Patent: January 29, 2013Assignee: TriLink BioTechnologies, Inc.Inventors: Gerald Zon, Alexandre Lebedev